Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Executive Summary

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Advertisement

Related Content

Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments
Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
More European Countries Agree To Swap Pricing Info And Negotiate Prices
Biogen Ventures Into Value-Based Contracts In Multiple Sclerosis
Large Employers Exploring Value-Based Contracting For Specialty Drugs
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel